Scarica l'app Stockscreener
41.30
13.74%
4.99
Dopo l'orario di chiusura:
41.45
0.15
+0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
Corcept’s relacorilant could reach $2.1B ovarian cancer market - BioWorld MedTech
Corcept’s Relacorilant May See All-Comers Advantage, If Approved - Citeline News & Insights
Corcept Therapeutics (NASDAQ:CORT) Shares Gap UpShould You Buy? - MarketBeat
Why Did Corcept Therapeutics Stock Surge Over 14% Today? - Asianet Newsable
Corcept Therapeutics Faces Pressure as Price Target Slashed Amid FDA Setback - StocksToTrade
Corcept Therapeutics (CORT) Sees Significant Stock Surge - GuruFocus
Why Is Corcept Therapeutics Stock Trading Higher Today?Corcept Therapeutics (NASDAQ:CORT) - Benzinga
Eagle Bancorp Posts Upbeat Q4 Results, Joins Corcept Therapeutics, LSI Industries And Other Big Stocks Moving Higher On Thursday - Benzinga
Why This Former Highflying Biotech Just Surged Again - Investor's Business Daily
Corcept Therapeutics (CORT) Surges 25% on Positive Trial Results - GuruFocus
Corcept posts trial win for ovarian cancer therapy (CORT:NASDAQ) - Seeking Alpha
Overall survival primary endpoint met in Corcept's pivotal phase 3 ROSELLA trial of relacorilant in patients with platinum-resistant ovarian cancer - marketscreener.com
Corcept Therapeutics stock soars after cancer drug meets survival endpoint By Investing.com - Investing.com Canada
Corcept Therapeutics Inc Announces Phase 3 Trial Success - TradingView — Track All Markets
In ROSELLA trial, relacorilant added 4.1 months survival in ovarian cancer - Stock Titan
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
QRG Capital Management Inc. Has $649,000 Stake in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm - PR Newswire
Market Overview: Should you avoid Corcept Therapeutics Incorporated stock right nowWeekly Risk Report & Verified Momentum Watchlists - baoquankhu1.vn
Rally Mode: Will Corcept Therapeutics Incorporated stock hit new highs in YEAR2025 Risk Factors & Verified Short-Term Plans - baoquankhu1.vn
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman - GlobeNewswire Inc.
Zacks Research Has Negative Forecast for CORT Q3 Earnings - MarketBeat
CORT Stock Price, Forecast & Analysis | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - Chartmill
Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts? - Finviz
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
Corcept Therapeutics (NASDAQ:CORT) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Nasdaq Composite Mechanism Strategy - Kalkine Media
CORT Investors Have Opportunity to Join Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics Under Investigation After FDA Response, Shares Plunge Over 50% - Intellectia AI
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire
Corcept Therapeutics Faces Investigation After FDA Response Letter, Shares Plunge Over 50% - Intellectia AI
DJS Law Group Investigates Corcept Therapeutics for Securities Violations - Intellectia AI
Corcept Therapeutics Incorporated Investigated on Behalf of InvestorsContact the DJS Law Group to Discuss Your Rights – CORT - marketscreener.com
INVESTOR ALERT: Investigation of Corcept Therapeutics Incorporated (CORT) by Holzer & Holzer, LLC - GlobeNewswire
Corcept’s growth hopes dented after FDA rebuff for Cushing’s drug - S&P Global
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50%Hagens Berman - PR Newswire
Corcept Therapeutics (BIT:1CORT) Price Target Decreased by 24.29% to 80.62 - Nasdaq
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AST SpaceMobile, Inc. - GlobeNewswire Inc.
CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - TradingView — Track All Markets
Inflation Data: Why is Corcept Therapeutics Incorporated stock going upJuly 2025 Opening Moves & Weekly Breakout Watchlists - baoquankhu1.vn
Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT) - marketscreener.com
Bank Watch: Why is Corcept Therapeutics Incorporated stock going upWeekly Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
CORT Investor ALERT: Corcept Therapeutics Inc. Investigated for Securities Fraud; Investors ... - bdtonline.com
CORT Investor ALERT: Corcept Therapeutics Inc. Investigated - GlobeNewswire
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day - Yahoo Finance
Why Corcept (CORT) stock is trading lower today - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Connect - ACCESS Newswire
H.C. Wainwright lifts Corcept stock target to $115 on drug outlook - MSN
Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT) - Business Wire
Will Corcept Therapeutics Incorporated (HTD) stock outperform benchmarksWeekly Market Outlook & AI Powered Buy/Sell Recommendations - ulpravda.ru
Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter - Finviz
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid - GlobeNewswire
Is Corcept Therapeutics Incorporated stock positioned for long term growthJuly 2025 Rallies & Capital Protection Trading Alerts - ulpravda.ru
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Corcept Therapeutics (CORT): Analyst says shares pricing in growth, new launch - MSN
Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells 20,000 Shares of Stock - MarketBeat
Guyer, Corcept therapeutics officer, sells $703k in shares By Investing.com - Investing.com Canada
CORT ALERT: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated for Possible Securities Fraud Violations - ACCESS Newswire
Is Corcept Therapeutics Incorporated stock in correction or buying zoneDip Buying & High Accuracy Investment Signals - ulpravda.ru
CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics ... - Bluefield Daily Telegraph
CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Why Corcept Therapeutics Incorporated stock is a must watch in 2025 - ulpravda.ru
Published on: 2026-01-08 22:12:30 - ulpravda.ru
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Yahoo Finance
0.46%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):